Alimera Sciences’ Iluvien™ Phase 3 Studies For DME Pass Final DSMB Review Prior To October Readout

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has re... [more]

View complete Press Release article